Physician profile
Casey Nelson
NPI 1477135267
$770.14
in general payments reported to CMS, 2019-2025
14 companies · $17.91 in 2025
The $17.91 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.77 · 2022: $202 · 2023: $207 · 2024: $265 · 2025: $17.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $211.06 | 2023-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $100.18 | 2022-2024 | |
| Lilly USA, LLC | $77.36 | 2022-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.01 | 2021-2023 | |
| Abbvie INC. | $67.31 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.15 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $42.97 | 2023 | Gvoke Hypopen |
| Hikma Pharmaceuticals USA | $32.82 | 2022 | |
| Amgen INC. | $31.66 | 2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $24.24 | 2021 | |
| Novo Nordisk INC | $16.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.34 | 2024 | Voquezna |
| Pfizer INC. | $14.05 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.